The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
IndiGo profit falls on higher cost on older planes
The airline was forced to induct older planes due to grounding led by issues of Pratt & Whitney engines